welcome fourth quarter full year financial result conference call participant listen mode operator instruction today presentation opportunity question operator instruction please note event record would like turn conference senior vice president investor relation please ahead senior vice president investor relation thank operator good afternoon everyone please welcome fourth quarter full year financial result conference call afternoon issue press release result press release support slide available website investor section event presentation page speaker today call president chief executive officer chip executive vice president commercial chief financial officer chief medical officer follow prepare remark open line question keep call hour limit question give everyone opportunity participate call today today conference call include forward look statement regard future anticipate event result include company financial outlook anticipate product sale revenue expense potential clinical regulatory milestone include data readout regulatory submission potential market reimbursement approval actual result development differ materially project imply forward look statement factor cause difference include difficulty forecast sale revenue expense impact relate pandemic uncertainty associate pharmaceutical development regulatory approval process information risk uncertainty face contain caption risk factor include company quarterly report form quarter file security exchange commission company subsequent report file turn call president chief executive officer thank good afternoon everyone today report billion product sale increase drive solid growth across commercial portfolio royalty revenue increase million year year increase reflect sale growth collaborator total revenue guidance billion billion exclude strong balance sheet cash position billion position advance pipeline internal external investment walk financial guidance first like begin reflect another exceptional year achieve important milestone continue expand global infrastructure portfolio begin commercial product standard care frontline lymphoma peripheral cell lymphoma form foundation core business revenue standpoint receive approval country partner continue provide important drug patient need notably last week announce phase clinical trial demonstrate statistically significant improvement overall survival advance lymphoma patient treat plus chemotherapy frontline year establish standard care treat disease almost year data regard intensify initially release thrill plus improve overall survival believe groundbreaking data demonstrate clinical value importance disease first class become standard care previously treat metastatic urothelial cancer broadly adopt oncologist treat patient date last year receive regular approval also grant cisplatin ineligible second line indication together partner secure approval progress regulatory submission across pacific receive positive opinion recently commission decision make process pause additional question relate severe skin reaction french compassionate access program side effect describe since launch manage prescribe physician believe risk benefit profile remain unchanged commit work authority important drug approve urothelial cancer patient beyond global regulatory activity advance robust clinical development program monotherapy combination earlier line therapy complete enrollment cohort expect data second half year could potentially support accelerate approval first line metastatic urothelial cancer also explore earlier stage bladder cancer represent larger market opportunity muscle invasive bladder cancer report neoadjuvant monotherapy data later month patient trial muscle invasive bladder cancer finally conduct basket trial evaluate express solid tumor best class tyrosine kinase inhibitor broad potential cancer overall survival data inclusion treatment guideline reflect clinical value second later line positive breast cancer patient without brain metastasis approve country commercially launch work secure reimbursement plan launch additional country course recently announce appointment executive vice president commercial international look forward contribution toward continue expansion strategic partnership merck extend reach outside broad clinical development program include positive breast cancer colorectal cancer gastric cancer amplify mutant tumor notably expect data phase trial second half year could potentially support accelerate approval colorectal cancer fourth approve product launch collaboration tissue factor target approve recurrent metastatic cervical cancer patient disease progression chemotherapy represent important drug disease characterize objective response rate poor outcome clinical development program design support global regulatory application maximize future potential cervical cancer solid tumor look expand cervical cancer recently present promise combination data earlier line treatment could lead much larger patient population also drive advancement across deep diverse pipeline example license late stage novel disitamab vedotin utilize high affinity antibody enhance internalization compare trastuzumab receive conditional approval third line gastric cancer recently second later line metastatic urothelial cancer clinical development program prioritize monotherapy combination approach breast bladder gastric cancer utilize vedotin base technology leverage expertise work maximize development potential value global reach turn earlier stage work recently initiate trial novel also submit clear develop technology order widen therapeutic window excite class drug focus improve tolerability addition four program proprietary sugar engineer antibody technology overall advance program across pipeline approve product range solid tumor hematologic malignancy next want provide brief update litigation recently arbitration hear record reopen consider additional evidence result decision occur first quarter previously anticipate achievement help bolster resilient core business solid foundation continue build upon expect achieve many milestone include important clinical data readout global regulatory commercial progress advance across pipeline help drive future growth look deliver continue innovation develop transformative therapy remain focus three area first work maximize potential approve portfolio exceptional commercial execution clinical development strategic partnership expand commercial portfolio four product year treat patient date robust clinical development program generate potential future label expansion opportunity second advance deep diverse pipeline asset look bring drug market come year believe leadership expertise empower antibody provide competitive advantage come expand progress pipeline finally position continue innovation growth build optimize infrastructure capability expand geographic footprint strategic partnership maximize ability reach patient across globe strong corporate development significant financial strength allow execute upon deal accelerate trajectory next turn call chip provide update commercial performance financial result guidance detail clinical development activity pipeline chip chip executive vice president commercial thank commercial deliver another strong quarter close successful year effectively scale execute effort maximize potential commercial portfolio four product fourth quarter sale million increase fourth quarter focus remain drive share frontline stage lymphoma please recent update treatment guideline recognize significance five year data excite overall survival data phase study continue monitor uptake frontline move fourth quarter sale million increase fourth quarter broad adoption checkpoint inhibitor maintenance therapy patient frontline metastatic help become prefer standard care second line post maintenance addition indication patient ineligible cisplatin contain chemotherapy continue represent meaningful option modest incremental growth opportunity expect growth drive exist indication look forward potentially promote additional patent label frontline metastatic urothelial cancer next year move fourth quarter sale million increase fourth quarter last year growth come remain utilize product second later line patient brain mets update overall survival data patient recently present breast cancer symposium receive promotional focus monitor evolve metastatic breast cancer treatment landscape incorporate annual revenue guidance detail shortly sale quarter continue grow look forward gain reimbursement additional country please sale million first full quarter since approval launch plan navigate care requirement gain valuable insight allow enhance educational effort although initial indication represent modest opportunity important treatment option early feedback positive turn call chief financial officer thank chip thank everyone join call afternoon financial result reflect significant advance make across business past year today summarize financial result outlook total revenue million fourth quarter billion full year include product sale million fourth quarter billion full year represent increase year reflect growth product sale across portfolio particularly royalty revenue million fourth quarter million year year year annual growth royalty revenue primarily drive increase sale lesser degree sale utilize technology collaboration revenue million fourth quarter million full year collaboration revenue decrease result million recognize fourth quarter million recognize full year amount relate ladiratuzumab vedotin collaboration merck enter sale million third quarter million full year include product sale royalty brand gross profit share collaborator noncash amortization acquire technology expense million fourth quarter billion full year increase include million upfront payment license disitamab vedotin continue investment across early late stage pipeline expense million fourth quarter million full year increase reflect investment support ongoing launch across recently launch next turn financial outlook begin revenue guidance across three commercial brand guide product sale billion billion represent increase sale expect range million million reflect modest growth advance broad clinical development program intend secure additional label sale project range million million expect growth drive primarily continue utilization within current indication expect report data cohort trial second half year guidance include impact potential label expansion sale expect range million million chip mention guidance reflect ongoing evolution treatment landscape expect report data trial later year colorectal cancer anticipate label expansion continue engage individual country authority secure broader reimbursement take year post approval since still early launch include sale estimate guidance time next expect royalty revenue range million million primarily reflect sale territory along contribution finally expect collaboration revenue range million million reminder collaboration revenue include profit share sale territory include royalty sale future year expect include profit share turn expense guidance sale expect range million million drive increase product sale across brand higher profit share payment collaborator sale also reflect third party royalty noncash amortization expense expect range billion billion primarily relate item first investment clinical trial expand additional indication second increase investment advance earlier stage agent include program pipeline believe investment important long term growth expense expect range million million continue focus commercial execution drive growth approve product guidance also include investment support global infrastructure continue launch noncash expense expect range million million majority stock base compensation take together guidance reflect strategy expand commercial opportunity portfolio advance product candidate turn call highlight development activity chief medical officer thank good afternoon everyone happy share recent clinical development update approve medicine pipeline begin extremely please combination significantly improve overall survival compare newly diagnose patient advance lymphoma show reduce risk death hazard ratio value data demonstrate meaningful difference bring patient look forward present result upcoming medical meet addition recently inform phase study newly diagnose pediatric patient high risk lymphoma define stage bulk meet primary endpoint event free survival report data safety monitor committee trial sponsor national cancer institute fund child oncology group study compare contain chemotherapy regimen chemotherapy regimen include bleomycin thank child oncology group effort look forward presentation excite data upcoming medical meet present initial data combination plus nivolumab dacarbazine frontline advance lymphoma show objective response rate complete response rate therapy believe promise result could form basis future test novel regimen frontline later year plan share result describe potential utility combination solid tumor also test phase study patient begin quarter turn remain focus important product earlier line urothelial cancer frontline metastatic evaluate study cohort patient ineligible cisplatin therapy include cisplatin eligible ineligible patient cohort complete enrollment expect report line result second half phase global trial assess plus compare platinum contain chemotherapy please trial project complete enrollment year intend confirmatory trial cohort support global market application muscle invasive bladder cancer together merck advance phase trial test combination perioperative treatment different population keynote trial cisplatin eligible patient keynote trial cisplatin ineligible patient later month plan present result exploratory cohort cohort monotherapy give neoadjuvant treatment cisplatin ineligible muscle invasive bladder cancer patient three cycle prior cystectomy furthermore please announce begin enrollment trial single agent muscle invasive bladder cancer study administer intravesically nonresponsive patient also study monotherapy basket trial high express solid tumor include lung breast head neck gastric esophageal cancer study continue enroll patient await initial data year inform next step turn continue advance broad development program breast malignancy solid tumor today highlight study evaluate frontline maintenance positive metastatic breast cancer standard care patient typically include eight cycle taxane otherwise know chemotherapy complete continue maintenance despite excellent result obtain patient remain risk relapse death include risk relapse brain patient complete receive alone primary endpoint progression free survival expect treat first patient quarter cancer await result phase study expect second half year study treatment patient previously treat positive colorectal cancer additional trial study combination oxaliplatin base chemotherapy first line cancer combination basket trial solid tumor turn receive accelerate approval unite state treatment patient recurrent metastatic cervical cancer disease progression chemotherapy global phase trial cervical cancer currently include plan expand region study intend serve confirmatory trial unite state importantly support global regulatory application next goal move earlier line metastatic recurrent cervical cancer regard present combination data trial first second line study expand investigate additional multidrug combination include combine carboplatin without bevacizumab result combination inform development first line beyond cervical cancer continue study potential malignancy ongoing phase trial preliminary data evaluate treatment head neck cancer present later month head neck cancer symposium turn disitamab vedotin second quarter year expect begin monotherapy trial urothelial cancer also focus development breast cancer base encourage monotherapy data generate partner like briefly mention early stage pipeline evaluate multiple product phase clinical trial across range solid tumor hematologic malignancy recently report first clinical data novel program disclose initial monotherapy data demonstrate encourage early safety efficacy profile first line plus multiple myeloma addition recently share data combination chemotherapy anti metastatic pancreatic cancer demonstrate evidence immune activation patient acceptable safety profile encourage antitumor activity follow survival ongoing inform future development decision also basket trial combination solid tumor include melanoma small cell lung cancer close continue make meaningful progress pipeline look forward provide update future call hand call back president chief executive officer thank proud important milestone achieve past year stage future portfolio prove commercial engine expand international infrastructure strategic partnership increase global competitiveness maximize value approve medicine believe significant financial strength active corporate development robust clinical development catalyst continue bolster deep diverse pipeline position future innovation growth point turn operator please open line question